Randal Mills left Osiris Therapeutics a few years after the company won the first-ever approval for a stem cell therapy and wasn't sure where he'd go next, but Mills ended up moving across the country to help California's stem cell research funding agency decide how best to spend its last $800m.
CIRM CEO Mills On California's Last $800m For Stem Cells
Randal Mills left Osiris Therapeutics a few years after the company won the first-ever approval for a stem cell therapy and wasn't sure where he'd go next, but Mills ended up moving across the country to help California's stem cell research funding agency decide how best to spend its last $800m.
More from Dermatological
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
More from Therapy Areas
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.